Helixgate

Helixgate

Uncategorized

STAT+: As artificial intelligence show off diagnostic chops, scientists reckon with the way forward

Getting a paper published in Science is a highlight of many researchers’ careers. But for internist and clinical AI researcher Adam Rodman, it’s also been a source of some agita. 

On Thursday, Rodman and his colleagues published a compilation of experiments, including one using real-world data from a Boston emergency department, that show a large language model from OpenAI can outperform physicians in case-based diagnostic and clinical reasoning evaluations. To Rodman, the paper’s co-senior author, it’s a response to a gauntlet thrown down in Science in 1959. That paper “described how you would know that a clinical decision support system was capable of doing diagnosis better than humans,” he said. “And they can do it.”

But as generative AI tools like chatbots are heavily marketed — both to patients and clinicians — it makes him worried that the science experiments, all based on simulated and historical cases, will be misconstrued as proof of AI’s safety and efficacy when used to treat real patients. 

Continue to STAT+ to read the full story…

Read More

Published

on

Getting a paper published in Science is a highlight of many researchers’ careers. But for internist and clinical AI researcher Adam Rodman, it’s also been a source of some agita. 

On Thursday, Rodman and his colleagues published a compilation of experiments, including one using real-world data from a Boston emergency department, that show a large language model from OpenAI can outperform physicians in case-based diagnostic and clinical reasoning evaluations. To Rodman, the paper’s co-senior author, it’s a response to a gauntlet thrown down in Science in 1959. That paper “described how you would know that a clinical decision support system was capable of doing diagnosis better than humans,” he said. “And they can do it.”

But as generative AI tools like chatbots are heavily marketed — both to patients and clinicians — it makes him worried that the science experiments, all based on simulated and historical cases, will be misconstrued as proof of AI’s safety and efficacy when used to treat real patients. 

Continue to STAT+ to read the full story…

Read More

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Celiac disease is entering a new era of therapeutic innovation

For the ~1 in 100 people living with celiac, the burden of disease extends far beyond their plate.

Read More

Published

on

For the ~1 in 100 people living with celiac, the burden of disease extends far beyond their plate.

Read More

Continue Reading

Uncategorized

The commercial launch playbook: Team structure, readiness and execution

Published

on

Intellia Therapeutics’s Senior Vice President Maria Natale discusses why the most successful launches are shaped long before approval, with strategy, structure and patient insight at the core.

Continue Reading

Uncategorized

Despite FDA trial clearance, ibogaine metabolite won’t receive red carpet treatment

Published

on

DemeRx is launching the first U.S. clinical trial of an ibogaine-derived drug candidate, marking a pivotal moment for a controversial psychedelic long sidelined by safety concerns.

Continue Reading
Advertisement

Trending